Back to search

Article

Immune recovery in tumor microenvironment of<i>TP53</i>-mutated AML following venetoclax combination therapy

2025-05-13

Abstract excerpt

<h4>Highlights</h4> Single-cell RNA sequencing of bone marrow from TP53-mutated AML patients showed a decrease in cells expressing anti-apoptotic genes like BCL2 and MCL1 after venetoclax and azacitidine treatment. Immune cells increased both in number and in gene expression levels associated with cytotoxicity post venetoclax combination therapy, verifying immune recovery. Residual AML cells expressed CD47 and CLL...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c4175183-144b-50e0-95c7-659dcf8a14b2
DOI
10.1101/2025.05.12.25327414
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immune recovery in tumor microenvironment of<i>TP53</i>-mutated AML following venetoclax combination therapyDOI 10.1101/2025.05.12.25327414
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cellsSemantic proximity
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Semantic proximity
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity
TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity
Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.Semantic proximity
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.